Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1272)	1/28/2000 4:52:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Friday January 28, 10:48 am Eastern Time Company Press Release SOURCE: Medarex, Inc. Medarex Files Registration Statement for Public Offering PRINCETON, N.J., Jan. 28 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a public offering of 1.75 million shares of Common Stock. (snip) Friday January 28, 9:22 am Eastern Time Company Press Release SOURCE: Abgenix, Inc. Abgenix Files Common Stock Offering of Up to 2.5 Million Shares Includes Up to 700,000 Shares to be Sold by Cell Genesys FREMONT, Calif., Jan. 28 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced that it has filed a Registration Statement on Form S-1 with the Securities and Exchange Commission. The registration statement covers a proposed offering of up to 2,500,000 shares of common stock and includes up to 700,000 shares of common stock to be sold by a selling stockholder, Cell Genesys, Inc. (Nasdaq: CEGE - news). To the extent the underwriters sell more than 2,500,000 shares of common stock, the underwriters have an option to purchase up to an additional 375,000 shares, of which 270,000 shares shall be from Abgenix and 105,000 shares shall be from the selling stockholder, Cell Genesys, Inc. (snip) Friday January 28, 8:45 am Eastern Time Company Press Release SOURCE: CuraGen Corporation CuraGen Raises $125 Million from the Sale of Convertible Debentures NEW HAVEN, Conn., Jan. 28 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN - news), a genomics based drug discovery and development company, announced today that it has entered into a purchase agreement providing for the sale to certain initial purchasers of $125 million aggregate principal amount of convertible subordinated debentures ($150 million if the over- allotment option is exercised in full). (snip) Friday January 28, 8:06 am Eastern Time Company Press Release Trimeris Raises Approximately $65 Million Through Private Placement DURHAM, N.C.--(BUSINESS WIRE)--Jan. 28, 2000--Trimeris, Inc. (Nasdaq: TRMS - news) today announced that it has offered and intends to complete a private placement of Trimeris' common stock to new and current shareholders in order to raise net proceeds of up to approximately $65 million. In connection with this private placement, the company intends to issue up to 1.75 million shares of common stock. Net proceeds from the private placement will be used to fund the clinical development of its product candidates, T-20 and T-1249, to fund increased research and development, to provide working capital and for general corporate purposes. (snip)